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The latest extensive studies on the treatment of lupus erythem-
atodes with gold compounds published in the United States are
those of Wright (1), Throne et al. (la) and Driver and Weller
(2). Much attention has been paid to the problem in other
countries, and a wealth of material has been accumulated which
we shall briefly evaluate inasmuch as this has not been done in
the foregoing studies. This task is facilitated by the publications
of Feliner (3) and Leitner (4) who each in his field give an accu-
rate résumé of our knowledge of the subject up to 1932 and 1934,
respectively, with a comprehensive index of the literature.
Hence, references included in these two papers will not be quoted.
Among the gold compounds which were more recently introduced, Solganat B
has been used extensively in Europe, especially Germany. It has largely replaced
the original Solganal because of its alleged lessened toxicity. Solganal B has
only the trade-name in common with its predecessor; chemically it is entirely dif-
ferent. For while Solganal is the disodium salt of 4-sulphomethyl-amino-2-auro-
mercaptophenyl-sulphonic acid, Solganal B is auro-thio-glykose (C611110,SAu).
In contrast to most of the other gold salts which are alkali compounds of aromatic
acids, Solganal B is an aliphatic neutral derivative with a gold content of 50 per
cent. Its toxicity is supposed to be 10 times less than that of Solganal; a guinea
pig tolerated as high a dosage as 0.3 per kilogram. Solganal B is given sub-
cutaneously or intramuscularly. The claim has been made CHurch and Von-
kennel (3)) that by administering the compound in an oily suspension the toxicity
is further lessened. The slower resorption of gold suspended in oil has been
demonstrated experimentally by Grassi (5). In this form Solganal B has been
marketed under the trade-name of Solganal B Oleosum as a 2 per cent and a
20 per cent suspension.
1 From the Section of Dermatology of the Department of Medicine, University
of Chicago, Chicago, Ill.
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Other compounds not included in Driver and Weller's study (2) are:
Aurosan, which is used mainly in Poland and is identical with Sanochrysin
(Sodium Gold Thiosulphate). French equivalents of the latter are marketed
under the name of Crisalbine and Thiocrysine. Auroprota8in is another gold
preparation on which only a few reports have been published (6).
The Italian Neocri8ol, a gold-arseno-benzol compound, and also Fosfakrisol
and Orotiol the—latter also of Italian source.
Gold chloride (AuCI,) which is given intravenously in a 1 per cent solution
was elaborated in Germany and is also used in this country. Greenbaum (7),
in this country, reports satisfactory results from the oral administration of gold
sodium chloride.
Auro-Detoxin which contains 12.5 per cent gold. This allegedly non-toxic
compound is considered by some investigators to be the best and safest gold
preparation (Pillokat (8), Engel (9)).
Myochrysine (Gold Sodium Thiomalate) which contains 50 per cent gold.
Coflaurin, which is a colloidal gold preparation containing 75 per cent gold
and 25 per cent protective colloid (it is given by mouth).
Aurocollargol, which is a combination of gold and silver in a colloidal state
(it is given intravenously). Gold content: 0.008 per cent. Silver content:
0.06 per cent. It is believed that the therapeutic effect of silver is increased
by the gold.
Solutions of colloidal gold for intravenous administration are also marketed
in this country by several pharmaceutical laboratories. However, sodium gold
thiosulphate is the only gold compound which has been recognized by the Council
on Pharmacy and Chemistry of the American Medical Association.
THERAPEUTIC USES
It can be said that in the chronic discoid form of lupus erythematodes gold
has maintained its position as the treatment of choice, while it is contra-indicated
in the acute and subacute forms of the disease. The only dissenting voice from
this axiom is that of Bechet (in discussion of Engman (10)) who states that gold
therapy is successful even in the acute forms of lupus erythematodes if extreme
caution is used. Knowles (in discussion of Engnian (10)) claims that gold is
well tolerated in acute lupus erythematode8 if given in the form of blood from
a donor who had two hours before received an intravenous injection of 100 mg.
of a gold preparation. Whether the minute amount of gold thus given has any
specific effect remains to be determined.
The French tendency of recent years to prefer bismuth to gold has not yet
been generally accepted, but is constantly gaining ground everywhere (Jordan
and Tarabuchin (11), Srokowska (12)). In this country bismuth treatment has
been favorably reported on by Ingels (13). Satisfactory treatment results by
local injections of gold as inaugurated by Traub (14) were obtained by Gougerot
and Burnier (15). Gougerot and Patte (16), however, warn against the possibility
of anaphylactic and humoral shock which they experienced in the use of this
method. The statement of Levin (17) that injection of gold directly into the
lesion not only led to the cure of the lesion but also the disappearance of tubercie-
bacilli in the sputum will have to be interpreted as a coincidence rather than a
causal effect. Our own experiences with this method were not favorable.
Whether the subcutaneous injection-method of Alden and Jones (18) (who used
a stable, buffered solution) offers any definite advantage remains to be seen.
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Treatment with gold compounds in the various forms of the tuberculids has
also met with success. Good results with gold alone have been published by many
investigators (3) in the treatment of erythema induratum Bazin, (tuberculosis
indurativa), papulo-necrotic tuberculids and acnitis (tuberculosis papulo-nec-
rotica) Boeck's sarcoid (latest report by Bureau et al. (19)) and lichen scro-
phulosorum (tuberculosis lichenoides). Erythema induratum seems to respond
especially well.
It is agreed by the majority of investigators that in true tuberculosis of the
skin gold therapy alone is insufficient. The tuberculous lesion may disappear
under the treatment, but the development of tuberculous manifestations in other
organs cannot be prevented (3); there is even a possibility of activation of latent
tuberculous foci in other organs by gold-therapy (20). Yet the results obtained
by the combination of other orthodox therapy plus gold administration have
proven the efficacy of gold as an adjunct in lupus vulgaris (Fellner (3), Nicolas
et al. (20)). Koga (21) and Epstein (22) have reported favorably on the treat-
ment of lupus disseminatus faciei with gold preparations.
The use of gold compounds in treating tuberculosis of the lungs, and in the
therapy of syphilis, and of leprosy, is beyond the scope of this paper. It may,
however, be mentioned that an increasing number of other diseases has been
subjected to treatment with gold. For example, Erysipelas has been successfully
treated with Solganal (3); in pyodermas Solganal B has given good results (23);
and tymphogranuloma inguinule was reported cured by the same compound
(8, 24, 25).
Moreover, arthritis deformans (26) and gonorrhoic arthritis (27) have been
treated successfully with gold and it seems that gold is also being used more and
more in this country for chronic arthritis.
For the sake of completeness it should be mentioned that in general attempts
which have been made to treat acne vulgaris (28) and psoriasis (la, 29, 30) with
gold compounds have not been successful. Throne and Myers (30a) claim that
gold treatment for psoriasis is not only of practically no value but that it is
contraindicated in this condition because of a decided tendency to reactions.
Epstein et al. (22), however, report satisfactory results in acne, especially acne
indurata. It is equally surprising to hear of good results in the treatment of
parapsoriasis (31). Since no form of therapy has thus far proven effective in
this obstinate dermatosis of unknown origin, the method seemed worth testing.
Following Gougerot's suggestion we subjected two cases of pityriasis lichenoides
chronica to prolonged treatment with ammonium succinimido-aurate but were
unable to observe any change in the eruption. The favorable reports on the
treatment of lichen planus (32, 33) are numerically insignificant in the face of
the overwhelming number of reports on lichen planus produced by gold therapy
(see skin-phenomena).
SKIN- AND MUCOUS-MEMBRANE PHENOMENA AS SEQUELAE OF
GOLD THERAPY
The early reports mention many toxic phenomena even including deaths;
and later authors have added a host of new and diversified observations (Fell-
ner, 3).
In the more recent literature the following cutaneous disorders have been
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reported: Erythroderma (34, 35, 36), generalized erythroderma following sub-
cutaneous injections (37), desquamation of feet and hands without erythema
(38), grave cutaneous and mucous membrane phenomena including persistent
total alopecia (39), dermatitis (40, 41), exfoliative dermatitis (42, 43, 44), eczema-
toid dermatitis of the seborrhoic type (45), gold eczema (46).
Four cases of keratoderma from gold therapy are reported (Irgang, 47, Rox-
burgh, 48). In one patient, traces of gold could be demonstrated in the kerato-
derma blenorrhagica-like lesions. In another case, the keratoderma was asso-
ciated with melanoderma. This seems to be the only report in the literature
where a primary melanoderma,—i.e., hyper-pigmentation without relation to a
preexisting eruption—has developed from the use of a gold compound. Gougerot
and Carteaud (3) observed a retiform pigmentation. Touraine and Voillemin
(49) a pigmentation "en nappes," Sezary et al. (50) a diffuse melanoderma.
These pigmentations, however, appeared at sites previously occupied by the
gold dermatitis, or erythroderma, respectively.
An interesting phenomenon, to which increased attention has been paid is
the pigmentation resulting from the deposition of gold in the skin, first reported
by Hansborg (3). Similar pigmentations from sanochrysin were observed by
Zimmerli and Lutz (3), Lopez (3), and, later on—from chrysalbine—by Josserand
(3), Gate (3), Charpy (3), Cuilleret (3), Gougerot et al. (51), Touraine and
Voillemin (49), Sézary et al. (52), Rathery et a!. (53). It seems to be more
frequently encountered in women, and—logically—patients with chrysiasis
(gold pigmentations) usually show no symptoms of intolerance to gold (54).
Cascos (55) has found that the difference between argyria and chrysiasis is only
physical in nature. The silver particles are of uniform size and comparatively
small, the gold particles less uniform and larger. Stillians, in his excellent report
on argyria (56), does not consider chrysiasis in differential diagnosis. Since the
clinical aspect'of the two conditions is practically the same, and the biospectric
method at present not simple enough to be possible for the practising derma-
tologist, it will be of interest to see whether the intradermal injection of reducing
fluid offers a differential-diagnostic test between chrysiasis and argyria. In
either chrysiasis or argyria the discoloration is often most evident upon the parts
of the skin which are exposed to light, as has been reported by Sallman (57),
Bernard et al. (58), Ramel (59), Cascos (60), and Fowler (61); the deposition
may also be present in the tissues of the eyes (conjunctiva and cornea—Sail-
man, 57). Lorenzen (3) had 28 cases of chrysiasis among 57 patients who were
treated with sanochrysin for tuberculosis of the lungs. He claims that the
appearance of the pigmentation depends upon the total amount of gold admin-
istered. No patient developed pigmentation who had received a total dose of
no more than 5 cg. per kilo but every patient who had been given 15 cg. per
kilo developed chrysiasis towards the end of the first year after treatment. The
intensity of the pigmentation reaches its peak during the second or third year.
The biospectrometric studies of the quantitative distribution of gold in the
body, as carried out by Gaul and Stand (62), represent a far more accurate method
of determining the minimum amount of gold which must be deposited in order
to produce the clinical picture of chrysiasis.
An explanation for the mechanism of chrysiasis is offered by Sallman (57):
Precious metals can be reduced easily; this reduction process is facilitated by
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the effect of intense exposure to ultra-violet light. Bernard and his co-workers
(58) found their three patients with chrysiasis sensitive to ultra-violet light.
Negret (63) sensitized the skin to light by means of intravenous injections of
Solganal. Gouin (64) goes so far as to assume that the action of ultra-violet
light is indispensable for the therapeutic effect of gold since the gold-salts are
activated in the body by ultra-violet light. In reference to this it may be re-
marked that Franck (65) reports the cure of a patient with lupus erythematodes
of the face by the combination of gold-treatment and intensive local irradiations
with ultra-violet light. In view of the generally acknowledged damaging effect
of ultra-violet light, statements like these seem surprising and further investi-
gations will be necessary to confirm or reject this theory.
The histo-chemical demonstration of gold has been accomplished many times
(Timm, 66, Policard et al., 67, Gerlach et al., 68, Bernard et al., 58, PrUsener, 69,
Hornus and Krassnoff, 70, Yamamato et al., 71, Gaul and Staud, 62) by staining
as well as by spectroscopic methods. Fischl and his coworkers (72) and Feldt
(73) have demonstrated gold in spirochetes and in trypanosomas. While the
former authors regard these findings as a proof of the direct chemo-therapeutie
effect of gold, the latter disproves this theory and claims that gold has no parasito-
trophic effect but increases the natural defense forces. Feldt found that normal
gold-sensitive spirochetes and gold-fast spirochetes both take up the same amount
of gold. That gold has no bactericidal effect on cultures of tubercle-bacilli is
reported by Courmont and his co-workers (74). Hornus and Krassnoff (70)
found that gold collects in tuberculous foci and believe that the effect of gold
therapy depends upon the presence of the metal in the diseased tissue where the
fight between the acid-fast bacilli and the reticulo-endothelial cells is taking
place. In this connection, the observation of Milian (75) who reported the
occurrence of a so-called "perifocal" erythema from gold therapy, localized
mainly in old and new tuberculous lesions, as well as that of Nicholas and Rous-
set (76) who observed purpuric lesions confined to the area of the healing lesions
of lupus erythematodes, is interesting.
Among the manifold varieties of skin eruptions due to gold treatment one
group deserves special attention, namely the toxic eruptions resembling infec-
tious diseases. The close similarity between scarlatina and gold dermatitis with
exanthem was pointed out by Laporte (77). Further observations led French
investigators to believe that these eruptions are not toxic (allergic) phenomena
but represent the infectious disease which they resemble. This is explained by
activation of latent organisms ("biotropisme" of Milian). In this country,
Keim (77a) has given an excellent report on the subject. In the case of gold
therapy such "Aurides biotropiques" may be produced by the same organism
for which the gold was administered, e.g., papulo-necrotic tuberculids in patients
under treatment for tuberculosis (the occurrence of tuberculids and of eruptions
simulating tuberculids has frequently been reported, see Fellner (3)) or dis-
semination of lupus erythematodes in patients treated for the chronic discoid
form (direct biotropism). Or, they may be produced by latent organisms the
existence of which was not known, e.g., measles in patients under treatment for
lupus erythematodes or scarlatina in patients under treatment for arthritic
conditions ("indirect biotropism"). Milian (78) recently observed the devel-
opment of icterus in a syphilitic patient while under gold treatment. He inter-
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preted the syphilitic icterus as another example of indirect biotropism. Asdéry
(79) who has reported on the subject claims that the characteristics for biotropie
phenomena consist in the acute appearance on the ninth day, the clinical aspect,
the fact that spontaneous involution will take place in spite of the continuation
of gold treatment and the negative reaction to intradermaltest8 with gold.
Whether or not the hypothesis of biotropism will be substantiated, the fact
remains that some gold eruptions present a differential diagnostic problem in
regard to certain infectious diseases. Also peculiar to gold (and, incidentally,
to bismuth) seems to be the imitation (?) of pityriasis rosea. Kiess and Strand-
berg reported one such case from Aurophos (3), Konrad one from Lopion (3) and
our own observations (see page 97) confirm their experiences.
Lichen planus seems to be the most common eruption attributable to gold
therapy (80, 81, 49, 82, 84, 85, 86, 87, 88, 89, 90). The lichen eruption may also
assume the form of lichen corneu8, verrucosus, or spinulosu8 (91, 92, 93, 93a). At
this point we wish to add a pertinent experience of our own:
A patient with lichenoid lupus erythematodes under treatment with sodium
gold thiosulphate developed an eruption in the form of lichen spinulosus. Thus
it seems that the individual reaction to various harmful agents in general re-
mained constant as far as the localization is concerned. The reaction to both,
to the unknown agents responsible for the lupus erythematodes and to the gold,
became and remained follicular. It is not a mere speculation if we assume that
this patient would have responded to other agents in the same particular way,
e.g., in the form of Bockhart's impetigo to a streptococcic infection or in the form
of a follicular seborrheic dermatitis, had he been subject to these affections. J.
Jadassohn's observations of follicular syphilids and follicular reactions to tuber-
culin frequently occurring in the same patients seem to support this hypothesis.
Sometimes the gold eruption presents a mixture of lichen planus and psoriasis
(82, 94, 83). Dermatitis herpetiformis has also been observed (26).
An interesting observation of a peculiar localization of gold dermatitis is
reported by Gougerot and Boucher (95): the areas involved were the ones exposed
to light and the sites of a previous dermatitis medicamentosa on the legs. Pills-
bury's (96) report on gold dermatitis in a patient with vitiligo, in whom the gold
dermatitis was limited to the depigmented skin is another example of the un-
known mechanism involved in the localization of reactions, and perhaps due to
the effects of light.
The situation as to the value of skin testing is still uncertain (97). Flandin
and his co-workers (98) believe that epidermal tests make it possible to differen-
tiate between eruptions due to individual sensitivity to gold and those of a
merely "toxic" nature. The statement of Gougerot and Degas (99) who claim
that polyvalent sensitivity to foods developed following erythroderma from
gold does not convince us in regard to proof of causal connection. Our experience
also disagrees with that of Lichtenstein (100) in regard to the value of patch
tests in dermatoses due to gold. We believe that further progress will have to
be made in the allergy problem as a whole before practical conclusions can be
drawn.
Of the attempts at desensitization, the method of Dainow (101) who claims
that by administration of ascorbic acid (vitamin C) signs of intolerance including
erythroderma can be overcome, deserves attention.
Dissemination of chronic lupus erythematodes by gold treatment which—
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according to Milian—would have to be interpreted as a biotropic rather than a
toxic effect, has been observed many times (1, 2, 3, 102, 103, and our own obser-
vations. See p. 94). The differential diagnosis between new lesions in the
dissemination of chronic lupus erythematodes and the lesions of a medicamentous
gold eruption sometimes becomes a difficult problem, and microscopic examina-
tion may be necessary to make the decision.
Involvement of the mucous membranes of the mouth is frequently associated
with cutaneous phenomena and may sometimes precede the cutaneous eruption.
The lesions are usually diffuse. Tenderness is present. Salivation is, as a rule,
not increased (Lebeuf and Mollard, 3). But bullous stomatitis (Gate, 104) and
ulcerative forms with necrosis (Kohrs, 3, Kren, 3, Gougerot and Blum, 105,
Flandin et al., 106) have also been reported. Milian (107) gives a review of
the clinic and therapy of gold stomatitis. Other reports are by Gougerot and
Burnier (83), Hallbaur (108), and Cordiviola (109). Isolated lichen planus of
the buccal mucous membrane was reported by Mohrmann (86), Schneidering
(110), and by Hölzer (111). Gold keratosis of the mouth was described by
Szanto (112). Systemic manifestations referable to internal organs resemble in
general those seen following the arsphenamines. It seems that reports of serious
damage to the internal organs have become relatively less frequent (Fellner, 3).
Renal damage has been reported lately by Kallo (113) and by Stopcryk (114).
Lombardo (115) has found that the first sign of a beginning auronephrosis is the
finding of the epithelial cast consisting of "cellule auriche."
Damage to the hemato-poietic system occurs not infrequently. Agranulo-
cytosis (Achard et al. 116, Ameuille and Braillon, 117, Margarat et al,, 118,
Chabaud et al., 119, Ellman and Lawrence, 120) may develop even from the use
of gold compounds which do not contain a benzene ring (Dameshek, 120a). Up
to the present, however, no damage to the hemato-poietic system could be pro-
duced in rabbits by the administration of gold (121).
The purpuric syndrome with fatal outcome has been reported by Achard et al.
(116), Fortunato (122), Vigne (123), and Cremer (124). Emile et al. (125) have
collected 30 cases of hemorrhagic disturbances. Further observations are re-
ported by Gougerot and Blum (126), Bie (127), Silveira (128). Intoxication with
blood changes may occur in spite of small doses (Armand-Delille et a!., 129,
Gougerot and Patte, 130). It is claimed by Gouin (131) that leukocytosis on the
second day following the first injection of gold is diagnostic for the presence of
tuberculosis, a statement which awaits confirmation.
Involvement of the re8piratory organs seems to be a rare occurrence. Core
(132) reports on rhino-pharyngo-stomatitis and edematous laryngitis, Coste et al.
(133) on gold bronchitis. The latter, being of the Milian school, interpret the
bronchitis as a biotropic phenomenon (see page 97).
Damages to the nervous system are fortunately rare. Hemiplegia, paralysis of
the radial nerve, and polyneuritis have been reported (3, 134). Of interest is the
loss of the sensory phenomenon of taste which followed immediately after the in-
jection (Solganal) and persisted for 6 weeks. Provocation of a recurrent polyra-
diculitis was reported by Chavany and Bourdillon (135). A fatal case of bulbar
asphyxia associated with erythroderma from gold was observed by Pierre-Bour-
geois et al. (136). Tuberculous meningitis following gold treatment (Lebeuf
and Mollard, 137) will have to be interpreted as a biotropic phenomenon (see
page 97).
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CHEMICAL CHARACTER AND TOXICITY OF SUCCINIMIDO
GOLD COMPOUND
The above review demonstrates that cumulative experience
indicates that there are significant hazards involved in gold-
therapy, particularly intravenous therapy.
However, considerable progress in the chemistry of organic
gold compounds has been made in recent years (Kharasch and
Isbell (138, 139, 140, 141), Kharasch and Beck (142)). It was
with the hope of finding a gold compound more satisfactory than
sodium gold thiosuiphate that this study was undertaken.
We decided to investigate at first a new class of organic gold
compounds prepared by Kharasch and Isbell (141), namely the
gold compounds of succinimide. These investigators record
that gold hydroxide reacts with succinimide in the presence of a
small amount of a halogen salt or mineral acid to yield a complex
in which the gold has a coordination number of four
0
C112—C
Au(OH)3 + 4 N—H/
dH2—.-c
0
0 1
C—Cl2/ +Au— N 11+31120
C—Cl2
0
It is very remarkable that the free "imido auric acids" (as these
compounds are called) are very strong acids and will form stable
ammonium, sodium and other salts. The salts yield colourless
solutions characterized by great stability toward both heat and
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reducing agents—a unique property for organic gold compounds.
Ammonium succinimido -aurate may be crystallized from hot
glacial acetic acid without decomposition.
Crystalline ammonium succinimido-aurate is a white powder
and has the following empirical formula: NH4Au(C411402N)4-
•41120. The water of crystallization may be removed by drying
the substance in an evacuated vessel over phosphorus pentoxide.
The compound is somewhat soluble in water. The presence,
however, of other salts, particularly salts of halides such as sodium
chloride, increases the solubility.2 The toxicity of the compound
was determined and found to be remarkably low for a gold
compound. Thus, one gram of the substance produced no toxic
symptoms in a rabbit of 3 kg., a result which stands in marked
contrast to the high toxicity of sodium gold thiosuiphate. In
our investigation a fresh solution was made for every patient.
The material was dissolved in boiling water, allowed to cool, and
administered intravenously. No definite concentration for ther-
apy was adopted. It varied with the individual dosage used.
The extreme limits of concentration employed were 0.005 to 1.0
gram of the substance in 5 to 10 cc. of physiological salt solution.
Recently, in order to decrease the amount of water used for
injection, the more soluble sodium salt of the imido-auric acid
was employed. This salt contains 28.4 per cent of gold and 8.6
per cent of nitrogen. A single dose of 300 mg. per kilogram
of weight is well tolerated by rabbits and guinea pigs. A dose
of 500 mg. per kilogram weight proved fatal within 5 days and
gold was demonstrated in most of the vital organs. Because
of the superior solubility and its low toxicity, the sodium suc-
cinimido aurate was exhaustively studied and submitted for the
approval of the Council on Pharmacy and Chemistry.
In order to evaluate this compound clinically, it was thought
desirable to compare its clinical effectiveness and toxicity with
that of sodium gold thiosuiphate. Furthermore, since lupus
erythematodes is the condition wherein gold treatment has its
greatest present applicability, it was decided to study the suc-
2 The material for our study was prepared for us by Dr. Ben C. Sher of the
Municipal Tuberculosis Sanatorium of Chicago.
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cinimido gold compound primarily in the treatment of this
disease.
CLINICAL DATA
Our clinical studies extended to the use of the succinimido
aurates in the treatment of lupus erythematodes, lupus vulgaris,
and other forms of skin tuberculosis.
In the ten years of operation of the University Clinics a total
of 117 patients with various forms of lupus erythematodes and
of cutaneous tuberculosis have come under our observation.
These we have classified as follows:
1. Lupus erythematodes in its various forms 86
2. Lupus miliaris disseminatus faciei 2
3. Lupus erythematoides of Leloir 1
4. Lupus vulgaris 7
5. Papulo-necrotic tuberculid 13
6. Erythema induratum 8
117
Since our extensive study of succinimido aurates was primarily
directed toward the treatment of lupus erythematodes, it is of
importance to classify further forms of this condition which came
under our observation, as well as other pertinent clinical data.
Total number of lupus erythematodes patients
Acute form 4
Subacute form 10
Chronic discoid form 61
Edematous form 7
Classification uncertain 4
86
Sez
32 male, 54 female
Age
Under 5 years 0
Between 6 and 15 4
Between 16 and 25 12
Between 26 and 35 30
Between 36 and 45 23
Between 46 and 55 10
Over 56 7
Total 86
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Location
Face 67
Ears 9
Scalp and hairline 15
Neck 8
Chest 4
Back 2
Trunk 1
Arms 6
Hands 3
Legs 0
Lips 10
Mucous membranes of mouth 4
Mucous membranes of genitalia 0
All mucous membranes 1
Definite clinical foci of infection
Tuberculosis of lungs 6
Tonsils 8
Teeth 10
Gallbladder 11
Kidney 1
Prostate gland 1
Arthritis 3
Of the 86 patients, 13 received no treatment, some because they
were referred only for diagnosis and some because of refusal to
take treatment. The remaining 73 patients received the mode of
treatment which by itself, or in combination with other methods,
seemed to be indicated in the individual case. The following
chemical compounds were used:
Ammonium and sodium succinimido-aurate by intravenous
injection (49 cases).Quinine sulphate by mouth (in all acute cases, in the sub-
acute cases as a preparatory phase of treatment, and in the
chronic recurrent forms during rest intervals between courses).
Sodium gold thiosuiphate by intravenous injection.
Gold sodium chloride (NaAuC14) by intravenous injection.
Neo-silver-arsphenamine by intravenous injection.
lodo-bismitol by intramuscular injection.
CO2 snow locally (in case of non-response).
'The two cases of infected gallbladder and infected kidney showed spectacu-
lar improvement following cholecystectomy and nephrectomy respectively but
recurrence followed subsequent acute infections (streptococcal sinusitis and
cystitis, respectively).
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CLINICAL RESULTS OF TREATMENT WITH SUCCINIMIDO GOLD COM-
POUNDS AND SODJUM GOLD THIOSULPHATE
Following the usual custom, in writing this paper we prepared
tables showing the number of patients who were improved, not
improved, aggravated, etc. However, those familiar with the
treatment of this tricky disease know the varied response of the
individual patient with lupus erythematodes to any mode of
treatment, the tendency to spontaneous involution in some cases,
the uncontrollable tendency to recurrence in others. Moreover,
a number of patients had been treated by several methods during
the course of the disease; others came to us after they had been
treated unsuccessfully with gold compounds elsewhere. Tabula-
tion of such varied data may thus lead to a great deal of con-
fusion, error in interpretation, and, sometimes may be definitely
misleading. It was thought best therefore to omit tables. The
following statement of our data and experience seems justifiable.
Under all conditions the gold succinimide compounds were as
effective as the sodium gold thiosuiphate although they seem to act
somewhat more slowly.
The contra-indications remain the same for both chemicals,
namely, their use in the treatment of the acute disseminated form
of the disease. It is our opinion that in this acute type treatment
should be limited to bed rest and large doses of quinine by mouth.
Although of equal therapeutic effectiveness, the marked advantage
of the succinimido-aurates over sodium gold thiosulphate consists in
the paucity and mildness of the untoward reactions with succinimido-
aurate. While severe reactions of the type recorded in the litera-
ture were observed with sodium gold thiosulphate, no severe
reactions and only the following mild upsets were seen with the
salts of succinimido aurates in the 49 patients under treatment.
Rise in temperature 1
Diarrhea 1
'This slower effect has perhaps found its explanation by recent excretion
studies carried out by Dr. Ben C. Sher which will be published separately. It
has been shown that far larger amounts of gold succinimides are excreted on
the first day than of sodium gold thiosulphate. Therefore it might be advisable
to give the injections twice a week instead of once a week in order to obtain a
more rapid effect.
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Slight nausea 2
Vomiting 2
Loss of appetite 1
Feeling tired 7
Headache 2
Abdominal pains 1
Flare-up of original skin lesions 2
Furthermore, the complete absence of dermatitis, erythro-
derma, exfoliative dermatitis, or purpura, is most striking. The
only eruptions which were observed after gold succinimide
therapy were the following:
One generalized macular eruption following the 4th injection.
One pityriasis-rosea-like eruption with lesions on the palms
and on the mucous membrane of the mouth.
One pityriasis-rosea-like eruption which closely simulated
ordinary pityriasis-rosea.
One erythematous, partly exudative eruption over the sternum
and on the upper back.
It is most significant that in 3 of these cases the eruptions
cleared up in from one to three months in spite of continuation of
the treatment with ammonium .succinimido-aurate. In the fourth
case, the administration of the gold salt was temporarily stopped
because of the possibility of acute dissemination of the patient's
lupus erythematodes. The eruption disappeared slowly under
treatment with quinine sulfate per os. Administration of am-
monium succinimido-aurate was resumed and the patient has
since shown no further skin manifestations attributable to gold
therapy.
The interpretation of these few mild eruptions due to gold
succinimide is difficult. Milian's school would probably interpret
them as biotropic (see page 96). In any case, since treatment
with the succinimido gold compound could be successfuly con-
tinued in spite of the presence of the eruption, if their nature was
allergic, a long lasting desensitization or refractory phase must
have been the rule. Patch tests on these four patients were
negative to ammonium succinimido aurate as well as to sodium
gold thiosulphate.
As to our general method of treatment of chronic lupus ery-
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thematodes, we wish to state that we recognize two essential
etiological factors which should be simultaneously combated in
order to achieve best results.
The first is the infectious factor, which today is generally
recognized regardless of whether the tubercie-bacifius, the strepto-
coccus or any other bacterial agent is responsibe in the individual
case. Thus far, most clinicians have been satisfied to treat
lupus erythematodes symptomatically, i.e., until the disappear-
ance of the lesions, and then to discharge the patient with the
admonition to return if the condition should recur. Such an
attitude is not unlike the one which prevailed in the old days
regarding syphilis. If we are dealing with a chronic infectious
disease as most investigators agree we are, it should be treated
not symptomatically but rationally. We feel that the chronic
lupus erythematodes patient is in a condition somewhat analogous
to the syphilitic patient and should receive alternating courses of
gold intravenously and of bismuth intramuscularly and rest
periods during which he is given quinine-sulphate per os. How
long this treatment should be continued to achieve permanent
results will—and to cite again the analogy with syphilis—be a
matter of experience, and it will take many years and a large
amount of clinical experimental data for an unequivocal answer.
The second factor, of equal importance, is fatigue. Stokes in
his discussion of Engman Jr.'s paper (10) has stressed a most sug-
gestive combination of allergic reaction and chronic exhaustion
which is commonly found in patients with lupus erythematodes.
As a matter of fact one of us (S. W. B—143) has stressed for
years the necessity of rest and relaxation in this disease and the
present trend of recognition of this factor is encouraging. We
wish to emphasize again the practical importance of this factor in
the treatment of not oniy the acute and subacute forms of lupus
erythematodes but in the chronic form as well.
CONCLUSIONS
1. The complex salts of the imido-auric-acids—in form of the
ammoruium or the sodium salt—represent gold compounds of
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low toxicity suitable for intravenous therapy where gold treat-
ment is indicated.
2. Their toxicity is much lower than that of sodium gold
thiosulphate.
3. When used in lupus erythematodes they show a therapeu-
tic effect similar to—but perhaps slower than—that of sodium
gold thiosuiphate.
4. In our experience untoward reactions from ammonium
succinimido-aurate are much less frequent and certainly less
serious than those from other gold compounds, particularly than
those from sodium gold thiosulphate.
5. Serious cutaneous phenomena have not been observed from
use of the new gold compound.
6. It is our opinion that the use of ammonium succinimido-
aurate makes gold therapy a safer procedure for the patient and
this gold compound is therefore recommended.
7. In chronic lupus erythematodes we recommend prolonged
rational treatment in the form of alternating intravenous courses
of gold and intramuscular bismuth injections, with interpolated
rest periods during which the patient is given quinine sulphate
by mouth. We recommend this method in place of the usual
symptomatic treatment, which generally ceases as soon as the
skin lesions have disappeared.
SUMMARY
The treatment of dermatoses with gold, its indications, contra-
indications and the toxic and allergic phenomena resulting from
the administration of gold preparations are discussed.
Results are reported on the employment of ammonium suc-
cinimido-aurate, a new gold compound of low toxicity, in the
treatment of 49 patients with lupus erythematodes The re-
ported observations extend over a period of six years. Thera-
peutic activity is slower than with certain other gold compounds,
such as sodium gold thiosulphate, but untoward reactions are
less frequent and less severe. Serious cutaneous phenomena
have never been observed. Ammonium succinimido-aurate is a
valuable addition in the therapy of lupus erythematodes.
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